Actualités

Record revenue masks payer headwinds forcing IBSRELA guidance cuts.

In August 2026, Ardelyx, Inc. reported second-quarter 2026 results showing revenue of US$120.88 million versus US$97.66 million a year earlier, with net loss narrowing to US$16.72 million and basic loss per share improving to US$0.07 from US$0.08. Alongside its results, Ardelyx updated full-year 2026 guidance, lifting expected IBSRELA revenue to US$350 million–US$370 million while keeping XPHOZAH revenue guidance steady at US$110 million–US$120 million, giving investors a clearer view of how...

Ardelyx Inc (ARDX) delivers 31% revenue growth in Q2 2026 while navigating payer-imposed challenges that led to a lowered Ibsrela outlook and withdrawal of Xphozah guidance.

Ardelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ardelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased paye

Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) reported first quarter 2026 results, with revenue of US$94.47 million and a net loss of US$37.61 million, and reiterated full-year revenue guidance for IBSRELA and XPHOZAH. See our latest analysis for Ardelyx. Ardelyx’s latest earnings release and guidance update come after a strong 1 year total shareholder return of 91.89%, while the 30 day share price return of 18.93% suggests momentum has picked up again around US$7.10. If this earnings driven move has you looking beyond...

Ardelyx Inc (ARDX) reports significant revenue increases for IBSRELA and XPHOZAH, while navigating operational challenges and investing in future growth.

Moby summary of Ardelyx, Inc.'s Q1 2026 earnings call

Michael Raab: Thank you. At Ardelyx, we are building an innovative pipeline of medicines for patients with unmet medical needs. As we build on this momentum, our focus is on executing on our four key priorities: accelerating the growth of Ibsrela, maintaining the Exposa momentum, building and expanding our pipeline, and delivering strong financial results.

Ardelyx (ARDX) delivered earnings and revenue surprises of -15.39% and +3.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with “another significant year of growth” underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.